CN1444977A - Medicine combination containing valid part of Ruyi Jinhuangsan and its preparing method - Google Patents
Medicine combination containing valid part of Ruyi Jinhuangsan and its preparing method Download PDFInfo
- Publication number
- CN1444977A CN1444977A CN 03113290 CN03113290A CN1444977A CN 1444977 A CN1444977 A CN 1444977A CN 03113290 CN03113290 CN 03113290 CN 03113290 A CN03113290 A CN 03113290A CN 1444977 A CN1444977 A CN 1444977A
- Authority
- CN
- China
- Prior art keywords
- parts
- wishes
- crude drug
- group
- glycerol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A Chinese medicine is prepared from 10 Chinese-medicinal materials including turmeric, dahurian angelica root, rhubarb, liquorice root, etc through extraction with alcohol, concentrating and adding lauryl azepinone. Its advantages are quickly taking its high effect, and high percutaneous absorbency.
Description
Technical field
The present invention relates to pharmaceutical composition that contains Chinese medicine compound ruyi jinhuang powder, ruyi jinhuang san effective site and preparation method thereof, specifically extract the effective site of ruyi jinhuang powder, ruyi jinhuang san, be mixed and made into all kinds of external preparation with suitable adjuvant.
Background technology
Ruyi jinhuang powder, ruyi jinhuang san is to go through edition kind that Pharmacopoeia of People's Republic of China recorded, and has the effect of reducing swelling and alleviating pain, is used for skin infection and swells and ache, and erysipelas stream is general, injury from falling down.Radix Et Rhizoma Rhei in the side, the detoxifcation of relieving inflammation or internal heat, promoting blood circulation and detumescence, the Cortex Phellodendri heat clearing and damp drying, removing toxic substances and promoting subsidence of swelling is monarch drug altogether; Be aided with Rhizoma Curcumae Longae, Radix Angelicae Dahuricae removing blood stasis with potent drugs promoting of the circulation of QI and removing the obstruction in the collaterals is dredged and is stopped up stagnant QI and blood, is accessory drugs; Arisaema Cum Bile, Rhizoma Atractylodis, Cortex Magnoliae Officinalis, Pericarpium Citri Reticulatae phlegm-eliminiating and qi-regulating, mass dissipating and swelling eliminating has the effect of crowding around of hoop collection; The pollen clearing heat for detumescence is adjuvant drug altogether; Radix Glycyrrhizae tool heat-clearing and toxic substances removing, and can coordinating the actions of various ingredients in a prescription be messenger drug.All medicines share, have relieve inflammation or internal heat, dissipating blood stasis, detumescence, pain relieving, the effect of crowding around.Yet powder uses very inconvenience, both affects the treatment, and also influences the scope of application and popularization.
Summary of the invention
The technical problem to be solved in the present invention is by analyzing the physicochemical property of effective site in the ruyi jinhuang powder, ruyi jinhuang san, design high efficiency extraction technology, and the effective site of ruyi jinhuang powder, ruyi jinhuang san combined with suitable adjuvant, prepare all kinds of external preparation with antibiotic, antiinflammatory, pain palliation efficacy, be specially and both can be used for skin infection and swell and ache, the erysipelas multiple abscess, injury from falling down can be used for decubital ulcer and phlebitic novel pharmaceutical formulation again.
External preparation of the present invention is compared with traditional ruyi jinhuang powder, ruyi jinhuang san, and not only easy to use, effect rapidly, effective component content is high, and the transdermal absorption factor height, active ingredient is stable, the preparation physicochemical character is stable, as external preparation, also needs coating performance good.
For addressing the above problem, the invention provides following technical solution.
A kind of externally-applied medicinal composition, available following method preparation:
Get 2～3 parts in Rhizoma Curcumae Longae, 2～3 parts of the Radixs Angelicae Dahuricae, 0.5～2 part of Pericarpium Citri Reticulatae, 0.5～2 part of Cortex Magnoliae Officinalis, 0.5～2 part of Rhizoma Atractylodis, with 85～95% ethanol percolations, the concentrating under reduced pressure percolate gets concentrated solution A to 5g crude drug/ml;
Get 2～3 parts of Radix Et Rhizoma Rhei, 2～3 parts of Cortex Phellodendris, 1 part in Radix Glycyrrhizae, 1 part of Arisaema Cum Bile, 4～6 parts of Radix Trichosanthis, with 55～65% alcohol reflux; Concentrate ethanol liquid to 2g or 4g crude drug/ml, get concentrated solution B;
Get 1 part of A concentrated solution by volume: B concentrated solution 0.5-1 part, mix with pharmaceutically acceptable carrier.
Described pharmaceutical composition is characterized in that:
Get 2.5 parts in Rhizoma Curcumae Longae, 2.5 parts of the Radixs Angelicae Dahuricae, 1 part of Pericarpium Citri Reticulatae, 1 part of Cortex Magnoliae Officinalis, 1 part of Rhizoma Atractylodis, use 90% ethanol percolation, the concentrating under reduced pressure percolate gets concentrated solution A to 5g crude drug/ml;
Get 2.5 parts of Radix Et Rhizoma Rhei, 2.5 parts of Cortex Phellodendris, 1 part in Radix Glycyrrhizae, 1 part of Arisaema Cum Bile, 5 parts of Radix Trichosanthis, with 8～10 times of amount 60% alcohol reflux; Concentrate ethanol liquid to 2g or 4g crude drug/ml, get concentrated solution B.
Aforementioned pharmaceutical composition can be made into liniment, ointment, tincture, unguentum or gel, rubber-emplastrum, emplastrum or cataplasma.
Liniment mainly is made up of with an amount of 50-75% ethanol 1 part of the B concentrated solution of 1 part of the A concentrated solution of 5g crude drug/ml by volume, 2g crude drug/ml.Also comprise 3～4.5% laurocaprams and/or dimethyl sulfoxide, 3～4.5% Tween-80s, polysorbate 60 and/or polysorbate 40,5～7% propylene glycol and/or PEG400 by volume in the liniment, and an amount of glycerol.
The preparation method of liniment comprises the steps:
Get 1 part of A concentrated solution and 3～4.5% laurocaprams and/or dimethyl sulfoxide mixing; Get 1 part of B concentrated solution and 3～4.5% polyoxyethylene sorbitan monoleate, polysorbate 60 and/or polysorbate 40,5～7% propylene glycol and/or PEG400 and an amount of glycerol mixing; Above-mentioned two liquid are mixed, add an amount of ethanol.
Ointment is mainly by 50 parts of the B concentrated solutions of 100 parts of the A concentrated solutions of 5g crude drug/ml, 4g crude drug/ml, with 30 POVIDONE K 30 BP/USP 30, beta-schardinger dextrin-and/or 15 20～40 parts of 30 POVIDONE K 30 BP/USPs, 10～30 parts of sodium lauryl sulphates, glycerol and/or 150～300 parts of PEG400, lanoline, vaseline and/or 18～38 parts of liquid paraffin, 20～40 parts of compositions of stearic acid by weight.Can comprise also in the ointment that 18～38 parts of hexadecanol, 6～18 parts, 1: 1 glycerol of glyceryl monostearate and aqueous mixtures are an amount of by weight, and the laurocapram of gross weight 2～4%.
Described ointment is basically by 50 parts of the B concentrated solutions of 100 parts of the A concentrated solutions of 5g crude drug/ml, 4g crude drug/ml, with 30 25～35 parts of 30 POVIDONE K 30 BP/USPs, 15～25 parts of sodium lauryl sulphates, 190～240 parts of glycerol, 22～30 parts of lanolines, 25～35 parts of stearic acid, 20～30 parts of hexadecanol, 8～14 parts, 1: 1 glycerol of glyceryl monostearate and aqueous mixtures are an amount of by weight, and the laurocapram of gross weight 2.5～3.5% is formed.
The preparation method of ointment comprises the steps:
100 parts of A concentrated solutions getting 5g crude drug/ml mix for 25～35 parts with 30 POVIDONE K 30 BP/USP 30, beta-schardinger dextrin-and/or 30 POVIDONE K 30 BP/USP makes dissolving, 1; Part mix 50 parts of B concentrated solutions getting 4g crude drug/ml and 15～25 parts of sodium lauryl sulphates and glycerol and/or PEG400190～240, heating in water bath, 2; Getting 20～30 parts of lanoline, vaseline and/or 22～30 parts of liquid paraffin, 25～35 parts of stearic acid, hexadecanol mixes for 8～14 parts with glyceryl monostearate, after the heat fused, add laurocapram, mixing by gross weight 2.5～3.5%, heat in the water-bath, get 3; Mix with 23, insulation 75 degree are cooled to 42～45 degree, as 4; 1 insulation to 35～40 degree, is added in 4, and 1: 1 the glycerol and the aqueous mixtures that replenish 35～40 degree are an amount of, natural condensation.
It is preferred that orthogonal test has been carried out in the extraction of Radix Et Rhizoma Rhei, Cortex Phellodendri, Arisaema Cum Bile, Radix Trichosanthis and Radix Glycyrrhizae, adopts ethanol extraction, and to the principal element concentration of alcohol of ethanol extraction, ethanol consumption and extraction time are carried out L by three factors, three levels
9(3)
4Orthogonal test.Result of the test shows that the principal element that influences extraction ratio is concentration of alcohol and ethanol consumption, to adopt 55～65% ethanol extractions better, is good with 60% ethanol extraction especially; Add 8～12 times of amounts and extract 2～3 times, got final product in each 1～2 hour, extract 2 times with 10 times of alcohol amounts, each 1.5 hours is good.
Radix Et Rhizoma Rhei mainly contains anthraquinone component, has antibiotic and antiinflammatory action.Cortex Phellodendri mainly contains the alkaloids composition, has effects such as antibiotic, antiviral, antifungal and antiinflammatory.Radix Glycyrrhizae mainly contains saponin component, has effects such as anti inflammatory immunity, antibiotic, antiviral.Rhizoma Arisaematis mainly contains compositions such as saponins, has analgesic activity.Radix Trichosanthis mainly contains trichosanthin and polysaccharide composition, has antibacterial action.Above Chinese medicine of the five flavours adopts alcohol reflux, serves as to investigate index with active ingredient emodin in the monarch drug Radix Et Rhizoma Rhei and the effective ingredient berberine hydrochloride in the Cortex Phellodendri, and its extraction ratio reaches 92.7% and 84.1% respectively, can more fully propose effective ingredient.
It is preferred that the extraction process of Rhizoma Curcumae Longae, the Radix Angelicae Dahuricae, Pericarpium Citri Reticulatae, Cortex Magnoliae Officinalis, Rhizoma Atractylodis has been carried out contrast, result of the test shows: 80～95% ethanol percolations are adopted in the extraction of Rhizoma Curcumae Longae, the Radix Angelicae Dahuricae, Pericarpium Citri Reticulatae, Cortex Magnoliae Officinalis, Rhizoma Atractylodis, preferred 90% ethanol percolation, the extraction efficiency height of effective ingredient curcumin, imperatorin and volatile oil not only, and dried cream yield is low, it is the effective component content height, especially it is higher to have Rhizoma Curcumae Longae volatile oil and curcumin content antibiotic and antiinflammatory and antiviral activity, and reduced and had thermo-labile, light fugitive photograph, the decomposition of the curcumin of water insoluble characteristic; All there is the Rhzoma Atractylodis Lanceae volatile oil of significant killing action to extract more complete to virus, mycoplasma, group B streptococcus, staphylococcus aureus, flavacin etc.; To Diplococcus pneumoniae, alpha streptococcus, catalin diplococcus, staphylococcus aureus all has the limonene in the very strong inhibiting Pericarpium Citri Reticulatae volatile oil, and the flavones ingredient Hesperidin with antiinflammatory, antiviral activity also extracts more complete; Also comprise compositions such as the volatile oil of Cortex Magnoliae Officinalis and lignanoid, lignanoid is mainly magnolol and honokiol, and magnolol has significant antibacterial action; Radix Angelicae Dahuricae volatile oil and Coumarins composition also extract more complete, and its volatile oil has antiinflammatory action, and Coumarins composition imperatorin has antibiotic, antiinflammatory action.Above Chinese medicine of the five flavours all contains volatile oil, and volatile oil not only is main effective ingredient, also has a transdermal facilitation.Antibiotic, antiinflammatory, disease-resistant composition are liposoluble constituent, therefore adopt ethanol percolate extraction, and cryoconcentration becomes thick paste, propose and keep volatile oil and be subject to pyrolysated active component.
Orthogonal test is adopted in research in the liniment preparation process, by the transdermal test in vitro absorption test, percutaneous absorption rate constant with the effective ingredient chrysophanol in the Radix Et Rhizoma Rhei is an index, and the amount of hanging the tall and erect ketone of nitrogen, polyoxyethylene sorbitan monoleate and propylene glycol the major influence factors pharmaceutical adjunct moon that influences Transdermal absorption is pressed three factors, three horizontal L
9(3)
4Orthogonal test.Result of the test shows that the principal element that influences Transdermal absorption is the amount of laurocapram, can add in the preparation and count 3～4.5% laurocaprams by volume, 3～4.5% Tween-80s, 5～7% propylene glycol; Add 4% laurocapram in the preparation, 4% polyoxyethylene sorbitan monoleate, 6% propylene glycol are good.
The cream preparation technical study at first adopts orthogonal test, has carried out preferred to the emulsifiable paste matrix prescription.With emulsion droplet size, appearance character and coating performance after the emulsifiable paste molding serves as to investigate index, and to principal element: the amount of the amount of the amount of lanoline, stearic amount, sodium lauryl sulphate, the amount of glyceryl monostearate, hexadecanol, the amount of glycerol and 30 POVIDONE K 30 BP/USP 30 carry out L by 7 factors, two levels
8(2)
7Orthogonal test.On the basis of above-mentioned preferred emulsifiable paste prescription, consumption (0%-4%) to the Percutaneous absorption enhancer laurocapram has carried out preferably, by the transdermal test in vitro absorption test, absorption rate constant with the effective ingredient chrysophanol in the Radix Et Rhizoma Rhei is an index, result of the test shows: it is better to add 2～4% laurocapram effect, the best results of 3% laurocapram.
Golden yellow liniment as one wishes and ointment pharmacodynamics test.
The comply with one's wishes golden yellow liniment and the golden yellow emulsifiable paste of complying with one's wishes shows through large and small Mus and Cavia porcellus result of the test: 1, significant analgesia role is arranged, can improve the pain threshold that causes of mice, that reduces that acetic acid causes turns round the body number of times; 2, have certain antiinflammatory action, suppress dimethylbenzene and cause the ear swelling of mice, Ovum Gallus domesticus album is caused that foot swelling of rat and the granulation hyperplasia that cotton balls causes also have the obvious suppression effect, there were significant differences with excipient group ratio.3, repercussive eliminating stagnation function well.The golden yellow liniment of complying with one's wishes can resist the blood stasis phenomenon that freely falling body produces rat with the golden yellow emulsifiable paste of complying with one's wishes, and the blood stasis tissue is taken an evident turn for the better.4, external bacteriostasis shows, the comply with one's wishes golden yellow liniment and the golden yellow emulsifiable paste of complying with one's wishes have to a certain degree inhibitory action to 6 kinds of antibacterials, and the golden yellow liniment of complying with one's wishes is to the strongest MIC of Candida albicans effect
50Be 3.12mg/ml, and the golden yellow emulsifiable paste of complying with one's wishes is to the strongest MIC of Candida albicans effect
50Be 6.25mg/ml, the local skin infection experiment shows that the comply with one's wishes golden yellow liniment and the golden yellow emulsifiable paste of complying with one's wishes obviously resist the skin infection that staphylococcus aureus causes, and make the very fast disappearance of purulence thing, ooze out minimizing, the ulcer surface reparation.5, itching-relieving action shows: this medicine obviously suppresses the effect of scratching where it itches that histamine produces.6, test shows to scytitis, and the comply with one's wishes golden yellow liniment and the golden yellow emulsifiable paste of complying with one's wishes can resist the mice dermatitis that 2,4 dinitrofluorobenzene produce.Illustrate that the golden yellow liniment of complying with one's wishes has good anti-inflammatory analgetic effect with the golden yellow emulsifiable paste of complying with one's wishes.
1, experiment material
Trial drug the present invention golden yellow emulsifiable paste (hereinafter to be referred as emulsifiable paste as one wishes) of complying with one's wishes, people's consumption 8g every day, every g emulsifiable paste contains crude drug amount 0.5g, is made by the inventive method.
The present invention's golden yellow liniment (hereinafter to be referred as liniment as one wishes) of complying with one's wishes, people's consumption 4g every day crude drug, every ml liniment contains crude drug amount 1g, is made by the inventive method.
Ruyi jinhuang powder, ruyi jinhuang san (loosing hereinafter to be referred as complying with one's wishes) is produced lot number: 010902-1 by Tianjin the 5th pharmaceutical factory of traditional Chinese medicine.
Experimental animal Kunming mouse Wistar rat, Cavia porcellus by Anhui Province medical university animal center provide that it is medium and small, the rat quality certification number, real moving accurate the 01st, No. 03 of Anhui doctor.
2, experimental technique
Analgesic test 2.1 (routine)
2.2 antiinflammatory test
2.2.1 xylol causes the inhibitory action of mice ear
Get 50 of body weight 18-22g male mices, abdominal part takes off row 3 * 3cm
2After be divided into 5 groups (the same) at random.The results are shown in Table 1,2.2.2.2 Ovum Gallus domesticus album is caused the inhibitory action of rat paw edema
Get 50 of body weight 180-220g male rats, abdominal part depilation 40cm
2After be divided into 5 groups at random, each group is with the same 2.1.1 of concentration, topical administration press the 0.5ml/100g body weight, suitably fixes continuous use 7 days.The results are shown in Table 3-6.2.2.3 cotton pellet method is caused the inhibitory action of rat granulation hyperplasia
Get 50 of body weight 180-220g male rats, the about 40cm of abdominal part depilation
2After, be divided into 5 groups at random, under the etherization aseptic condition, through autoclaving, each cotton balls adds ampicillin 1mg/0 with the cotton balls of having weighed, 1ml, after 50 ℃ of oven dry, it is subcutaneous to implant rat right side groin.The results are shown in Table 7,8.
2.3 wound is caused the effect of stasis of blood model
Get 60 of body weight 200-250g rats, the right hind depilation, behind the 24h, be divided into 6 groups at random, other rat right hind legs at different levels are separately fixed on the bottom platform of homemade freely falling body device except that normal group, freely fall from the 15cm eminence with 50 gram counterweights, continuous 5 times, cause the hind leg blood stasis and cause the wound rat model, then at the blood stasis position by table 13 dosage topical administration (liniment concentration is respectively 50,25,12.5%) 0.5ml/100g body weight, continuous 4d.The result is as follows.2.3.1 all there is obvious swelling each Mus part after the perusal modeling, blue, the oozing of blood of local skin, and the treatment back still has the mild swelling except that the model group part, and all the other each groups do not see that obvious pathological changes is arranged.2.3.2 mirror is observed down and is found the ruyi jinhuang powder, ruyi jinhuang san group and the large, medium and small dosage group of the golden yellow liniment group pathological changes that complies with one's wishes all has than model group and alleviates, and illustrate that golden yellow liniment as one wishes has certain therapeutic effect to skin, flesh wound.2.4 antibacterial tests 2.4.1 in-vitro antibacterial test 2.4.1.1 strain and culture medium: strain: staphylococcus aureus 10 strains (containing type strain ATCC25923), alpha streptococcus 8 strains, group B streptococcus 5 strains, escherichia coli 9 strains (containing reference culture ATCC25922), bacillus pyocyaneus 10 strains, Candida albicans 7 strains, more than 6 kind of 49 strain bacterial strain, wherein reference culture is preserved the center from Beijing biological product check institute strain, and all the other bacterial strains provide by first and second clinical cultivation of attached institute of Anhui Chinese Medicine College.Strain was write " national Clinical Laboratory rule of operation " in 1997 according to Ministry of Public Health Department of Medical Administration and is identified.
Culture medium is selected the MH culture medium for use; Candida albicans is selected husky Bao Shi maintenance base for use; Detest O
2Bacterium is with detesting O
2Culture medium.2.4.1.2MIC test
The preparation of pastille culture medium: in cultivating, add good as one wishes golden yellow liniment medicinal liquid of prepared beforehand and ruyi jinhuang powder, ruyi jinhuang san contrast medicine respectively, make the drug level of culture medium be respectively 200mg/ml, 100mg/ml, 50mg/ml, 25mg/ml, 12.5mg/ml, 6.25mg/ml, 3.125mg/ml, 1.56mg/ml with two-fold dilution's method for examination.
Confession examination bacterial classification inoculation: once (bacteria containing amount is about 10 to get confession examination bacterium liquid respectively with inoculating loop
4CFU/ml) be inoculated on the culture medium of different pharmaceutical concentration, hatch for 37 ℃ and cultivate 24h, after Candida albicans was cultivated 48h, observed result the results are shown in Table 9,10.2.4.2 antagonism bacterial skin infections test 2.4.2.1 test method is got 60 of the Kunming mouses that body weight is 18-22g, male and female half and half, every Mus back depilation 3 * 3cm
2, skin is frayed to oozing of blood with sand paper in depilation place, except that staying 10 mices to do the normal group, it does mice is 3 * 10 at the damaged skin subcutaneous injection through the prerun bacterial concentration
8The staphylococcus aureus 0.5ml of CFU/ml, every day 1 time, continuous 3 times, the skin appearance is red and swollen, the purulence thing oozes out, ulcer etc. infected phenomenons after 5 days.With infecting mouse be divided into model group, ruyi jinhuang powder, ruyi jinhuang san group (50%) at random, the golden yellow liniment of complying with one's wishes is little, in, heavy dose of group (12.5%, 25%, 50), successive administration 5 days (being coated with dose 0.1ml/10g body weight) according to dosage, wherein normal group and model group are given isodose excipient.2.4.2.2 result of the test
1, perusal:
(1) behind the injection golden Portugal bacterium, local skin swelling has ulcer, has purulence, inflammatory thing to ooze out, and normal group skin is without any reaction, and it is normal that the skin of galling recovers.
(2) after the medication, after the 1st medication respectively organized in treatment, inflammatory exudation stops, the purulence thing disappears, ulcer surface dwindles, beginning in the 2nd day, and obviously visible skin begins to repair, rubescent, incrustation, cut off skin and find have the congestion necrosis except that indivedual mices are subcutaneous, the overwhelming majority is subcutaneous not to have obvious difference with normal group; Beginning in the 3rd day, crust comes off, and skin is repaired substantially.And model group ulcer increases the weight of, and purulence, inflammatory thing ooze out and increase, and ulcer surface strengthens, and cuts off skin and finds that mice is subcutaneous to be had outside obvious congestion, the necrosis, with the normal group ratio, significant difference is arranged.
2, mirror is observed down:
Normal control group epidermis and subcutaneous tissue there is no pathological changes; The model group epidermis all has ulcer, and ulcer surface has a large amount of neutrophilic leukocytees and fiber to ooze out, and subcutaneous tissue has lamellar necrosis and microabscess to form, and hyperemia, edema, cell infiltration and hemorrhage are arranged around the pathological changes; The most of ulcer of medication group is not obvious, but inflammatory exudation is arranged, and downright bad abscess only appears at the minority animal in the subcutaneous tissue, and congestion and edema, cell infiltration also have and alleviate.Wherein the sick amount of group is light in a small amount.Positive group pathological changes also has and alleviates.
2.5 antipruritic test
Get 50 of body weight 250-300 Cavia porcelluss, medicine is spread upon left fore cropping zone, every the 0.1ml/100g of local application body weight, concentration is the same, behind the 40min, in the histamine phosphate 0.05ml/100g of forelimb intradermal injection 0.2% body weight, the results are shown in Table 11,12.
Golden yellow liniment is to 2 2.6 comply with one's wishes, the inhibitory action of the dermatitis that the 4-dinitrofluorobenzene produces
Getting body weight is 50 of 25-30g mices, and random packet is the same.Be coated with 0.5% 2,4-dinitrofluorobenzene (DNFB) 25 μ l sensitization, simultaneously with contain crude drug amount 50%, 25%, 12.5% liniment and 50% JINHUANG SAN by 0.1ml/ dosage continuously left ear administration 6 days, be coated with 0.25%DNFB20 μ l at the hard of hearing face in a mice left side in 6 hours and bring out dermatitis behind the 6th day medicine, auris dextra is coated with the solvent of equivalent.The results are shown in Table 13,14.
Table 1, the golden yellow liniment xylol of complying with one's wishes cause inhibitory action (n=10, the x ± s) of mice ear
Group number of animals (n) dosage (g/kg) swelling degree (mg) suppression ratio (%)
Excipient group 10 equivalent 0.0122 ± 0.0017/
The group 10 5.00 0.0084 ± 0.0014 of loosing complies with one's wishes
*15.00
Liniment group (little) 10 1.25 0.0107 ± 0.0013 12.00 complies with one's wishes
Liniment group as one wishes (in) 10 2.50 0.0094 ± 0.0012
*22.80
Liniment group (greatly) 10 5.00 0.0087 ± 0.0010 complies with one's wishes
*28.79
With the excipient group than * P＜0.05
Table 2, the golden yellow emulsifiable paste xylol of complying with one's wishes cause inhibitory action (n=10, the x ± s) of mice ear
Group number of animals (n) dosage (g/kg) swelling degree (mg) suppression ratio (%)
Excipient group 10 equivalent 0.0114 ± 0.0018/
The group 10 5.00 0.0090 ± 0.0019 of loosing complies with one's wishes
*21.40
Emulsifiable paste group (little) 10 1.25 0.0091 ± 0.0021 complies with one's wishes
*20.79
Emulsifiable paste group as one wishes (in) 10 2.50 0.0032 ± 0.0011
*28.73
Emulsifiable paste group (greatly) 10 5.00 0.0082 ± 0.0020 complies with one's wishes
*28.65
With the excipient group than * P＜0.05 * * P＜0.01
Table 3, the golden yellow liniment of complying with one's wishes cause inhibitory action (n=10, the x ± s) of rat paw edema to Ovum Gallus domesticus album
Dosage swelling degree (ml)
Group
(g/kg)
Normal value 0.5 1 1.5 23 (h)
Excipient group equivalent 1.67 ± 0.16 1.19 ± 0.25 1.45 ± 0.18 1.55 ± 0.16 1.37 ± 0.13 1.18 ± 0.13
The group 2.500 1.69 ± 0.11 1.18 ± 0.15 1.24 ± 0.16 1.15 ± 0.20 of loosing complies with one's wishes
*1.00 ± 0.15
*0.80 ± 0.13
*
Liniment group (little) 0.625 1.64 ± 0.14 1.12 ± 0.20 1.30 ± 0.22 1.37 ± 0.24 1.13 ± 0.24 complies with one's wishes
*0.89 ± 0.24
*
Liniment group as one wishes (in) 1.250 1.68 ± 0.19 0.94 ± 0.28
*1.20 ± 0.30
*1.14 ± 0.42
*1.01 ± 0.35
*0.84 ± 0.30
*
Liniment group (greatly) 2.500 1.66 ± 0.17 0.65 ± 0.29 complies with one's wishes
*0.84 ± 0.27
*1.07 ± 0.41
*1.03 ± 0.32
*0.77 ± 0.27
*
With the excipient group than * P＜0.05 * * P＜0.01
Table 4, comply with one's wishes golden yellow emulsifiable paste to Ovum Gallus domesticus album cause rat paw edema inhibitory action (n=10, x ± s)-
Dosage swelling degree (ml)
Group
(g/kg)
Normal value 0.5 1 1.5 23 (h)
Excipient group equivalent 1.67 ± 0.18 1.09 ± 0.20 1.41 ± 0.24 1.51 ± 0.17 .44 ± 0.26 1.44 ± 0.30
The group 2.500 1.62 ± 0.18 0.98 ± 0.24 1.34 ± 0.15 1.38 ± 0.19 1.13 ± 0.28 of loosing complies with one's wishes
*0.98 ± 0.31
*
Emulsifiable paste group (little) 0.625 1.68 ± 0.18 1.02 ± 0.34 1.37 ± 0.32 1.38 ± 0.24 1.09 ± 0.26 complies with one's wishes
*0.91 ± 0.25
*
Emulsifiable paste group as one wishes (in) 1.250 1.67 ± 0.23 1.04 ± 0.36 1.41 ± 0.27 1.26 ± 0.31
*1.05 ± 0.28
*0.81 ± 0.23
*
Emulsifiable paste group (greatly) 2.500 1.64 ± 0.21 1.05 ± 0.46 1.31 ± 0.31 1.24 ± 0.24 complies with one's wishes
*1.04 ± 0.25
*0.88 ± 0.23
*
With the excipient group than * P＜0.05 * * P＜0.01
Table 5, the golden yellow liniment of complying with one's wishes cause suppression ratio (n=10, the x ± s) of rat paw edema to Ovum Gallus domesticus album
Dosage suppression ratio (%)
Group
(g/kg) 0.5 1 1.5 2 3(h)
Excipient group equivalent // ///
The group 2.500 0.84 14.48 25.80 27.00 32.20 of loosing complies with one's wishes
Liniment group (little) 0.625 5.88 10.34 11.60 17.50 24.60 complies with one's wishes
Liniment group as one wishes (in) 1.250 21.00 17.24 26.45 26.30 28.89
Liniment group (greatly) 2.500 45.40 42.10 30.96 24.80 34.70 complies with one's wishes
Table 6, the golden yellow emulsifiable paste of complying with one's wishes cause suppression ratio (n=10, the x ± s) of rat paw edema to Ovum Gallus domesticus album
Group dosage suppression ratio (%)
Not other (g/kg) 0.5 1 1.5 23 (h)
Excipient group equivalent // ///
The group 2.500 11.92 4.96 8.61 21.53 31.94 of loosing complies with one's wishes
Emulsifiable paste group (little) 0.625 6.42 2.84 8.61 24.31 36.81 complies with one's wishes
Emulsifiable paste group as one wishes (in) 1.250 4.59 0.00 16.56 27.08 43.75
Emulsifiable paste group (greatly) 2.500 3.67 7.09 17.88 27.78 38.89 complies with one's wishes
Table 7, the golden yellow liniment of complying with one's wishes cause inhibitory action (n=10, the x ± s) of rat granulation hyperplasia to cotton pellet method
Group dosage granulation heavy (g)
Not other (g/kg) weight in wet base suppression ratio (g) dry weight suppression ratio (%)
Excipient group equivalent 0.6550 ± 0.0780/0.1427 ± 0.0089/
The group 2.500 0.5588 ± 0.0927 of loosing complies with one's wishes
*14.69 0.1070 ± 0.0200
*25.02
Liniment group (little) 0.625 0.6048 ± 0.1056 7.66 0.1184 ± 0.0140 complies with one's wishes
*17.03
Liniment group as one wishes (in) 1.250 0.5414 ± 0.0943 17.34 0.1072 ± 0.0109
*24.88
Liniment group (greatly) 2.500 0.5445 ± 0.1945 complies with one's wishes
*16.87 0.0846 ± 0.0303
*40.71
Table 8, the golden yellow emulsifiable paste of complying with one's wishes cause inhibitory action (n=10, the x ± s) of rat granulation hyperplasia to cotton pellet method
Group dosage granulation heavy (g)
Not other (g/kg) weight in wet base suppression ratio (%) dry weight suppression ratio (%)
Excipient group equivalent 0.5924 ± 0.1585/0.1309 ± 0.0167/
The group 2.500 0.4756 ± 0.622 of loosing complies with one's wishes
*19.70 0.1006 ± 0.0149
*23.50
Emulsifiable paste group (little) 0.625 0.5531 ± 0.0530 6.63 0.1000 ± 0.0129 complies with one's wishes
*23.61
Emulsifiable paste group as one wishes (in) 1.250 0.5154 ± 0.6556 13.00 0.0973 ± 0.0115
*25.67
Emulsifiable paste group (greatly) 2.500 0.4748 ± 0.0468 complies with one's wishes
*19.84 0.0980 ± 0.0083
*25.15
Table 9, the golden yellow liniment agent that complies with one's wishes are to 6 kind of 49 strain antibacterial MIC measurement result
Strain (strain number) ruyi jinhuang powder, ruyi jinhuang san (mg/ml) golden yellow liniment agent (mg/ml) blank solvent contrast as one wishes
MIC
R MIC
50 MIC
90 MIC
R MIC
50 MIC
90
Staphylococcus aureus (10) 6.25-50 25 25 3.12-12.5 12.5 6.25 00
Alpha streptococcus (8) 25-50 100 50 12.5-25 25 25 00
Group B streptococcus (5) 100-100 100 100 50-100 100 50 00
Escherichia coli (9) 100-200 200 100 6.25-100 25 12.5 00
Bacillus pyocyaneus (10) 100-200 200 200 50-100 100 100 00
Candida albicans (7) 12.5-50 50 50 1.56-6.25 3.12 3.12 00
Table 10, the golden yellow emulsifiable paste of complying with one's wishes are to 6 kind of 49 strain antibacterial MIC measurement result
Strain (strain number) golden yellow emulsifiable paste (mg/ml) ruyi jinhuang powder, ruyi jinhuang san (mg/ml) of complying with one's wishes
MIC
R MIC
90 MIC
50 MIC
R MIC
90 MIC
50
Staphylococcus aureus (10) 6.25-12.5 12.5 6.25 6.25-50 25 25
Alpha streptococcus (8) 25-100 100 50 25-100 100 50
Group B streptococcus (5) 50-100 100 100 100-100 100 100
Bacillus pyocyaneus (10) 100-200 200 100 100-200 200 200
Escherichia coli (9) 50-200 200 100 100-200 200 200
Candida albicans (6) 12.5-50 50 50 12.5-200 200 200
Table 11, (inferior) the golden yellow liniment of complying with one's wishes cause the effect of itching (n=10,10, x ± s) to antihistamine
Group number of animals (n) dosage (g/kg) number of times (inferior) suppression ratio (%) of scratching where it itches
Excipient group 10 equivalent 22.80 ± 2.90/
The group 10 0.500 13.00 ± 3.50 42.98 of loosing complies with one's wishes
Liniment group (little) 10 0.125 14.60 ± 3.37 35.96 complies with one's wishes
Liniment group as one wishes (in) 10 0.250 10.60 ± 2.50 53.51
Liniment group (greatly) 10 0.500 9.40 ± 2.37 58.77 complies with one's wishes
The result shows by table 17: the golden yellow liniment agent that complies with one's wishes causes to itch to histamine phosphate obvious inhibitory action, with excipient group ratio, notable difference is arranged.
Table 12, the golden yellow emulsifiable paste of complying with one's wishes cause the effect of itching (n=10, x ± s) to antihistamine
Group number of animals (n) dosage (g/kg) number of times (inferior) suppression ratio (%) of scratching where it itches
Excipient group 10 equivalent 22.20 ± 2.35/
The group 10 0.500 11.70 ± 3.77 of loosing complies with one's wishes
*42.08
Emulsifiable paste group (little) 10 0.125 17.50 ± 3.34 13.37 complies with one's wishes
Emulsifiable paste group as one wishes (in) 10 0.250 11.00 ± 3.40
*45.54
Emulsifiable paste group (greatly) 10 0.500 9.40 ± 3.17 complies with one's wishes
*53.47
With the vehicle group ratio
*P＜0.05
*P＜0.01
Table 13, the golden yellow liniment agent that complies with one's wishes be to 2, and the inhibitory action of the dermatitis that the 4-dinitrofluorobenzene produces (n=10, x ± s)
Group dosage ear thickness difference (mm) ear weight difference
(g/ only) left ear difference left and right sides ear difference (g)
Excipient group equivalent 0.077 ± 0.014 0.061 ± 0.015 0.0044 ± 0.0010
The group 0.0500 0.065 ± 0.026 0.055 ± 0.011 0.0036 ± 0.0030 of loosing complies with one's wishes
*
Gel group (little) 0.0125 0.068 ± 0.027 0.057 ± 0.012 0.0044 ± 0.0006 complies with one's wishes
Gel group as one wishes (in) 0.0250 0.059 ± 0.014 0.046 ± 0.011
*0.0033 ± 0.0010
*
Gel group (greatly) 0.0500 0.060 ± 0.018 0.041 ± 0.0120 complies with one's wishes
*0.0031 ± 0.0008
*
With the excipient group than * P＜0.05 * * P＜0.01
Table 14, the golden yellow emulsifiable paste of complying with one's wishes be to 2, and the inhibitory action of the dermatitis that the 4-dinitrofluorobenzene produces (n=10, x ± s)
Group dosage ear thickness difference (mm) ear weight difference
(g/ only) left ear difference left and right sides ear difference (g)
Excipient group equivalent 0.067 ± 0.067 0.066 ± 0.028 0.0445 ± 0.0009
The group 0.0500 0.055 ± 0.024 0.044 ± 0.018 0.0026 ± 0.0010 of loosing complies with one's wishes
*
Emulsifiable paste group (little) 0.0125 0.055 ± 0.020 0.061 ± 0.017 0.0029 ± 0.0012 complies with one's wishes
*
Emulsifiable paste group as one wishes (in) 0.0250 0.053 ± 0.025 0.052 ± 0.016 0.0031 ± 0.0007
*
Emulsifiable paste group (greatly) 0.0500 0.056 ± 0.029 0.044 ± 0.012 complies with one's wishes
*0.0023 ± 0.0007
*
With the excipient group than * P＜0.05 * * P＜0.01
From result of the test as seen: the comply with one's wishes golden yellow liniment and the golden yellow emulsifiable paste of complying with one's wishes have good repercussive analgesic effect, are in particular in: 1, significant analgesia role is arranged, can improve the pain threshold of mice, that reduces that acetic acid causes turns round the body number of times; 2, have certain antiinflammatory ability, can suppress dimethylbenzene and cause mice ear, the granulation hyperplasia that rat paw edema that Ovum Gallus domesticus album is caused and cotton balls cause rat also has the obvious suppression effect, with the excipient group than there were significant differences.3, the test of repercussive eliminating stagnation shows: the comply with one's wishes golden yellow liniment and the golden yellow emulsifiable paste of complying with one's wishes can resist the blood stasis phenomenon that freely falling body produces.4, external bacteriostasis shows, the comply with one's wishes golden yellow liniment and the golden yellow emulsifiable paste of complying with one's wishes have certain inhibitory action to 6 kinds of antibacterials, and the golden yellow liniment of wherein complying with one's wishes is to the strongest MIC of Candida albicans effect
503.12mg/ml; And the golden yellow emulsifiable paste of complying with one's wishes is to the strongest MIC of candida albicans
506.25mg/ml the local skin infection experiment shows that the comply with one's wishes golden yellow liniment and the golden yellow emulsifiable paste of complying with one's wishes obviously resist the skin infection that staphylococcus aureus causes, and make the very fast disappearance of purulence thing, ooze out minimizing, the ulcer surface reparation.5, itching-relieving action shows: this medicine has obviously antipruritic to scratching of antihistamine generation.6, test shows to scytitis, and the comply with one's wishes golden yellow liniment and the golden yellow emulsifiable paste of complying with one's wishes can resist 2, the dermatitis that the 4-dinitrofluorobenzene produces.Illustrate that the golden yellow liniment of complying with one's wishes has tangible analgesia, antiinflammatory, repercussive and itching relieving effect with the golden yellow emulsifiable paste external that complies with one's wishes.
The specific embodiment
Embodiment 1
Get Rhizoma Curcumae Longae 2.5kg, Radix Angelicae Dahuricae 2.5kg, Rhizoma Atractylodis 1kg, Pericarpium Citri Reticulatae 1kg, Cortex Magnoliae Officinalis 1kg, add 90% ethanol percolation, collect and just filter liquid 8L, carried out determination of volatile oil routinely as A liquid.Continue to collect the continuous liquid 80L that filters, decompression recycling ethanol is concentrated into every 1ml and is equivalent to contain the 5g crude drug; Other gets Radix Et Rhizoma Rhei 2.5kg, Cortex Phellodendri 2.5kg, Radix Trichosanthis 5kg, Radix Glycyrrhizae 1.25kg, Arisaema Cum Bile 1.25kg.Add 10 times of amount 60% alcohol reflux 2 times, each 1.5 hours, filter, merging filtrate reclaims ethanol, is concentrated into every 1ml and is equivalent to contain the 2g crude drug; Merge concentrated solution, as B liquid.Carrying out chrysophanol HPLC routinely measures.
Embodiment 2
Golden yellow liniment as one wishes: get A liquid 4L and add laurocapram 400ml, mixing; Other gets B liquid 4L and adds the about 400ml of polyoxyethylene sorbitan monoleate and propylene glycol 600ml and glycerol 1000ml, mixing; Above-mentioned two liquid are mixed, and adding 65% ethanol to full dose is 10L.Put 0-10 ℃ of cold preservation 24 hours, filter, embedding, check, promptly.
Embodiment 3
Golden yellow liniment as one wishes: get A liquid 4L and B liquid 4L, two liquid mix, and adding 70% ethanol to full dose is 10L.Put 0-10 ℃ of cold preservation 24 hours, filter, embedding, check, promptly.
Embodiment 4
Golden yellow liniment as one wishes: get A liquid 4L and add dimethyl sulfoxide 400ml, mixing; Other gets B liquid 4L and adds the about 400ml of polysorbate 40 and PEG 400ml and 60% ethanol 1000ml, mixing; Above-mentioned two liquid are mixed, and adding 60% ethanol to full dose is 10L.Put 0-10 ℃ of cold preservation 24 hours, filter, embedding, check, promptly.
Embodiment 5
The golden yellow emulsifiable paste of complying with one's wishes: get A liquid 4L, add PVPK30 1.2kg, stir and make dissolving, as 1.; B liquid is concentrated into every 1ml contains the solution that is equivalent to the 4g crude drug, get 2L, glycerol adding 4kg and lauryl sodium sulfate aqueous solution (400g is dissolved in the 3.2L water) are mixed, and after 30 minutes, move to 75 ℃ of water-baths in the boiling water bath heating, as 2.; With lanoline 1.12kg, stearic acid 1.26kg, hexadecanol 1.12kg, glyceryl monostearate 0.5kg, after heating is dissolved, add laurocapram 0.66L, mixing is put boiling water bath heating 30 minutes, is cooled to 75 ℃, as 3.; During the limit edged stirred and 3. slowly adds 2., insulated and stirred 10 minutes continued to be stirred to temperature and reduces to 42-45 ℃, and the insulation conduct 4.; To 1. be incubated to stir to 35-40 ℃ of back edged and slowly add 4., and weigh, mixed liquor to the total amount of replenishing glycerol-water (1: 1) of 35-40 ℃ is 20kg, insulated and stirred evenly after, constantly be stirred to the nature condensation.The degassing, packing, promptly.
Embodiment 6
A liquid 195ml
B liquid (the 195ml of 4g crude drug/ml)
30 POVIDONE K 30 BP/USP 30 60g
Sodium lauryl sulphate 20g
Glycerol 200g
Lanoline 56g
Stearic acid 63g
Hexadecanol 56g
Glyceryl monostearate 25g
Glycerol-water (1: 1) is an amount of
Make 1000g
Adding adds the laurocapram of weight ratio 3% by gross weight 1000g.Preparation method is with embodiment 5.
In the present embodiment, hexadecanol, glyceryl monostearate, laurocapram, glycerol-water (1: 1) all can omit.30 POVIDONE K 30 BP/USP 30 can substitute with beta-schardinger dextrin-or 30 POVIDONE K 30 BP/USP 15.Glycerol can substitute with PEG400.Lanoline can substitute with vaseline or liquid paraffin.
Embodiment 7
Golden yellow gel as one wishes: get carbomer 0.28kg, add water 7L, stirring and dissolving leaves standstill and got 4% carbomer gel in 24 hours; Get B liquid 4L, add propylene glycol 1.6kg, stirring and evenly mixing, the limit edged stirs and is added in the carbomer hydrogel, stirs, and under agitation adds triethanolamine and transfers PH5～8, stirs, and is standby; Get A liquid 4L, add the 0.6kg laurocapram, mixing, the limit edged stirs and is added in the above-mentioned initial gel, stirs, and adds water to 20kg, abundant mixing, packing, promptly.
Embodiment 8
A liquid 195ml
B liquid 195ml
Carbomer 14g
Propylene glycol 80g
Laurocapram 30g
Triethanolamine is an amount of
Water is an amount of
Make 1000g
Method is with embodiment 7.
Claims (10)
1, a kind of externally-applied medicinal composition, available following method preparation:
Get 2～3 parts in Rhizoma Curcumae Longae, 2～3 parts of the Radixs Angelicae Dahuricae, 0.5～2 part of Pericarpium Citri Reticulatae, 0.5～2 part of Cortex Magnoliae Officinalis, 0.5～2 part of Rhizoma Atractylodis, with 85～95% ethanol percolations, the concentrating under reduced pressure percolate gets concentrated solution A to 5g crude drug/ml;
Get 2～3 parts of Radix Et Rhizoma Rhei, 2～3 parts of Cortex Phellodendris, 1 part in Radix Glycyrrhizae, 1 part of Arisaema Cum Bile, 4～6 parts of Radix Trichosanthis, with 55～65% alcohol reflux; Concentrate ethanol liquid to 2g or 4g crude drug/ml, get concentrated solution B;
Get 1 part of A concentrated solution by volume: B concentrated solution 0.5-1 part, mix with pharmaceutically acceptable carrier.
2, according to the described pharmaceutical composition of claim 1, it is characterized in that:
Get 2.5 parts in Rhizoma Curcumae Longae, 2.5 parts of the Radixs Angelicae Dahuricae, 1 part of Pericarpium Citri Reticulatae, 1 part of Cortex Magnoliae Officinalis, 1 part of Rhizoma Atractylodis, use 90% ethanol percolation, the concentrating under reduced pressure percolate gets concentrated solution A to 5g crude drug/ml;
Get 2.5 parts of Radix Et Rhizoma Rhei, 2.5 parts of Cortex Phellodendris, 1 part in Radix Glycyrrhizae, 1 part of Arisaema Cum Bile, 5 parts of Radix Trichosanthis, with 8～10 times of amount 60% alcohol reflux; Concentrate ethanol liquid to 2g or 4g crude drug/ml, get concentrated solution B.
3, according to claim 1 or 2 described pharmaceutical compositions, it is characterized in that: make liniment, ointment, tincture, unguentum, rubber-emplastrum, emplastrum, gel or cataplasma.
4, according to the described pharmaceutical composition of claim 3, it is characterized in that: liniment mainly is made up of with an amount of 50-75% ethanol 1 part of the B concentrated solution of 1 part of the A concentrated solution of 5g crude drug/ml by volume, 2g crude drug/ml.
5, according to the described pharmaceutical composition of claim 4, it is characterized in that: also comprise 3～4.5% laurocaprams and/or dimethyl sulfoxide, 3～4.5% Tween-80s, polysorbate 60 and/or polysorbate 40,5～7% propylene glycol and/or PEG400 by volume in the liniment, and an amount of glycerol.
6, claim 4 or 5 described preparation of drug combination methods is characterized in that comprising the steps:
Get 1 part of A concentrated solution and 3～4.5% laurocaprams and/or dimethyl sulfoxide mixing; Get 1 part of B concentrated solution and 3～4.5% polyoxyethylene sorbitan monoleate, polysorbate 60 and/or polysorbate 40,5～7% propylene glycol and/or PEG400 and an amount of glycerol mixing; Above-mentioned two liquid are mixed, add an amount of ethanol.
7, according to the described pharmaceutical composition of claim 3, it is characterized in that: ointment is mainly by 50 parts of the B concentrated solutions of 100 parts of the A concentrated solutions of 5g crude drug/ml, 4g crude drug/ml, with 30 POVIDONE K 30 BP/USP 30, beta-schardinger dextrin-and/or 1520～40 parts of 30 POVIDONE K 30 BP/USPs, 10～30 parts of sodium lauryl sulphates, glycerol and/or PEG400150～300 by weight part, lanoline, vaseline and/or 18～38 parts of liquid paraffin, 20～40 parts of compositions of stearic acid.
8, according to the described pharmaceutical composition of claim 7, it is characterized in that: comprise also in the ointment that 18～38 parts of hexadecanol, 6～18 parts, 1: 1 glycerol of glyceryl monostearate and aqueous mixtures are an amount of by weight, and the laurocapram of gross weight 2～4%.
9, described according to Claim 8 pharmaceutical composition, it is characterized in that: ointment is basically by 50 parts of the B concentrated solutions of 100 parts of the A concentrated solutions of 5g crude drug/ml, 4g crude drug/ml, with 30 25～35 parts of 30 POVIDONE K 30 BP/USPs, 15～25 parts of sodium lauryl sulphates, 190～240 parts of glycerol, 22～30 parts of lanolines, 25～35 parts of stearic acid, 20～30 parts of hexadecanol, 8～14 parts, 1: 1 glycerol of glyceryl monostearate and aqueous mixtures are an amount of by weight, and the laurocapram of gross weight 2.5～3.5% is formed.
10, the described preparation of drug combination method of one of claim 7～9 is characterized in that comprising the steps:
100 parts of A concentrated solutions getting 5g crude drug/ml mix for 25～35 parts with 30 POVIDONE K 30 BP/USP 30, beta-schardinger dextrin-and/or 30 POVIDONE K 30 BP/USP makes dissolving, 1;
Part mix 50 parts of B concentrated solutions getting 4g crude drug/ml and 15～25 parts of sodium lauryl sulphates and glycerol and/or PEG400190～240, heating in water bath, 2;
Getting 20～30 parts of lanoline, vaseline and/or 22～30 parts of liquid paraffin, 25～35 parts of stearic acid, hexadecanol mixes for 8～14 parts with glyceryl monostearate, after the heat fused, add laurocapram, mixing by gross weight 2.5～3.5%, heat in the water-bath, get 3;
Mix with 23, insulation 75 degree are cooled to 42～45 degree, as 4;
1 insulation to 35～40 degree, is added in 4, and 1: 1 the glycerol and the aqueous mixtures that replenish 35～40 degree are an amount of, natural condensation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031132901A CN1308030C (en) | 2003-04-25 | 2003-04-25 | Medicine combination containing valid part of Ruyi Jinhuangsan and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031132901A CN1308030C (en) | 2003-04-25 | 2003-04-25 | Medicine combination containing valid part of Ruyi Jinhuangsan and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1444977A true CN1444977A (en) | 2003-10-01 |
| CN1308030C CN1308030C (en) | 2007-04-04 |
Family
ID=27814688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031132901A Expired - Fee Related CN1308030C (en) | 2003-04-25 | 2003-04-25 | Medicine combination containing valid part of Ruyi Jinhuangsan and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1308030C (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100333720C (en) * | 2005-01-11 | 2007-08-29 | 中国人民解放军第二军医大学 | Compound analgesic agent |
| CN100340230C (en) * | 2004-07-23 | 2007-10-03 | 童玉新 | 'Ruyi Jinhuang' gel and method for preparing the same |
| CN101288760B (en) * | 2008-06-18 | 2012-07-25 | 张松柏 | Externally-used drug for treating appendicitis |
| CN103393918A (en) * | 2013-07-25 | 2013-11-20 | 山西省中医药研究院 | Compounded garcinia and radix angelicae ointment for preventing and treating chemotherapeutic phlebitis |
| CN106833973A (en) * | 2017-01-18 | 2017-06-13 | 广西南宁博智生物科技有限公司 | A kind of cold process soap for acne of dispelling and preparation method thereof |
| CN109453343A (en) * | 2018-12-26 | 2019-03-12 | 贾力力 | A kind of Traditional Chinese medicinal poultice for treating skin sore rash |
| CN110680892A (en) * | 2018-07-04 | 2020-01-14 | 黑龙江燎原科技有限公司 | Cataplasm hot patch for relieving pain of tumor |
| CN110694011A (en) * | 2019-11-07 | 2020-01-17 | 刘兰香 | External application medicine for infantile phlebotomy injury phlebitis |
| CN111588824A (en) * | 2020-06-30 | 2020-08-28 | 南昌市第九医院 | Traditional Chinese medicine composition for repairing vein treatment part and preparation and use method |
| CN112121134A (en) * | 2020-08-26 | 2020-12-25 | 王利娟 | Traditional Chinese medicine composition for treating joint cavity effusion and preparation method thereof |
| CN115154571A (en) * | 2022-08-18 | 2022-10-11 | 西南民族大学 | Antibacterial composition and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1163762A (en) * | 1996-04-26 | 1997-11-05 | 韩殿卫 | Chinese patent medicine for treating tracheitis and emphysema |
| CN1191746A (en) * | 1998-03-05 | 1998-09-02 | 韩殿卫 | Chinese medicine for treating inflammation |
| CN1365781A (en) * | 2001-01-19 | 2002-08-28 | 杨孟君 | Nano medicine 'Ruyi Jinhuang' and its preparing process |
-
2003
- 2003-04-25 CN CNB031132901A patent/CN1308030C/en not_active Expired - Fee Related
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100340230C (en) * | 2004-07-23 | 2007-10-03 | 童玉新 | 'Ruyi Jinhuang' gel and method for preparing the same |
| CN100333720C (en) * | 2005-01-11 | 2007-08-29 | 中国人民解放军第二军医大学 | Compound analgesic agent |
| CN101288760B (en) * | 2008-06-18 | 2012-07-25 | 张松柏 | Externally-used drug for treating appendicitis |
| CN103393918A (en) * | 2013-07-25 | 2013-11-20 | 山西省中医药研究院 | Compounded garcinia and radix angelicae ointment for preventing and treating chemotherapeutic phlebitis |
| CN103393918B (en) * | 2013-07-25 | 2015-01-28 | 山西省中医药研究院 | Compounded garcinia and radix angelicae ointment for preventing and treating chemotherapeutic phlebitis |
| CN106833973A (en) * | 2017-01-18 | 2017-06-13 | 广西南宁博智生物科技有限公司 | A kind of cold process soap for acne of dispelling and preparation method thereof |
| CN110680892A (en) * | 2018-07-04 | 2020-01-14 | 黑龙江燎原科技有限公司 | Cataplasm hot patch for relieving pain of tumor |
| CN109453343A (en) * | 2018-12-26 | 2019-03-12 | 贾力力 | A kind of Traditional Chinese medicinal poultice for treating skin sore rash |
| CN110694011A (en) * | 2019-11-07 | 2020-01-17 | 刘兰香 | External application medicine for infantile phlebotomy injury phlebitis |
| CN111588824A (en) * | 2020-06-30 | 2020-08-28 | 南昌市第九医院 | Traditional Chinese medicine composition for repairing vein treatment part and preparation and use method |
| CN112121134A (en) * | 2020-08-26 | 2020-12-25 | 王利娟 | Traditional Chinese medicine composition for treating joint cavity effusion and preparation method thereof |
| CN115154571A (en) * | 2022-08-18 | 2022-10-11 | 西南民族大学 | Antibacterial composition and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1308030C (en) | 2007-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1444977A (en) | Medicine combination containing valid part of Ruyi Jinhuangsan and its preparing method | |
| CN1762967A (en) | Enoxolone derivative, preparation method and uses | |
| CN1772136A (en) | Medicine composition for treating soft tissue damage and osteoarthropathy and its prepn process | |
| CN1927293A (en) | Chinese medicine composition for treating skin burn and scald | |
| CN1895535A (en) | Chinese-medicinal preparation for treating gutture disease and it making method | |
| CN1843402A (en) | Drop pill for pharynx health and its preparation method | |
| CN1513447A (en) | Application of bamboo leaf total flavone in medicine for treating and preventing prostata disease and health-care-food | |
| CN1739767A (en) | Compound recipe capable of protecting liver and improving symptoms of hepatosis | |
| CN1246008C (en) | Chinese medicine preparation for curing acute and chronic rhinitis and its production method | |
| CN1947756A (en) | Formula of seven herbs medicine composition for relieving internal heat and invigorating blood circulation, its prepn. process and use | |
| CN1056298C (en) | External use medicine for treating soft tissue injury and its producing method | |
| CN100337650C (en) | Liquid medicine composition for external-applied anti-inflammation and antipruritic | |
| CN1823982A (en) | Chinese medicinal preparation for liver soothing and speen fortifying and its manufacturing method | |
| CN1608648A (en) | Antiseptic Chinese medicine composition and its prepn process | |
| CN1163227C (en) | Application of tanhin polyphenolic B magnesium in preparing medicine for treating chronic hepatosis | |
| CN1509741A (en) | Chinese medicinal preparation for preventing herpes virus and preparing method thereof | |
| CN1686241A (en) | Tupistra Chinensis Bak extract medicinal composition, and its preparation method and use same | |
| CN1298351C (en) | Chinese medicine oral preparaton for treating urinary system infestation and its preparation method | |
| CN1219527C (en) | Ointment for curing acne and its preparation method | |
| CN1895592A (en) | Chinese-medicinal compound preparation for treating acne and its preparation | |
| CN106692411B (en) | Antifungal infection resisting pharmaceutical composition, preparation method, preparation and application thereof | |
| CN1682819A (en) | Sihuang intense heat purging dripping pill and its preparing method | |
| CN1220515C (en) | Medicine for treating throat disease | |
| CN1616018A (en) | Preparation for improving bioavailability and medicine effect for treating gynecopathy and preparing method | |
| CN1839948A (en) | Externally applied Chinese traditional medicine formulation and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20131021 Granted publication date: 20070404 |
|
| RINS | Preservation of patent right or utility model and its discharge | ||
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20140421 Granted publication date: 20070404 |
|
| RINS | Preservation of patent right or utility model and its discharge | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070404 Termination date: 20140425 |